Eagle Pharmaceuticals, Inc. Aktie News

-- Single dose, IV amisulpride (10 mg) results in sustained antiemetic effect with supratherapeutic plasma levels of drug being maintained for at least 24 hours in patients requiring PONV rescue versus placebo -- -- Single dose, IV amisulpride (10 mg) results in sustained antiemetic effect with supratherapeutic plasma levels of drug being maintained for at least 24 hours in patients requiring P...

WOODCLIFF LAKE, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company”) today announced that it received a notice (the “Notice”) on April 8, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that due to the Company's failure to timely file its Annual Report on Form 10-K for the fiscal year e...

NEW YORK, NY / ACCESSWIRE / February 9, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/eagle-pharmaceuticals-inc-lawsuit-submission-form?prid=66577&wire=1 or contact Joseph E. Levi, Esq.

If you suffered losses exceeding $100,000 investing in Eagle Pharmaceuticals stock or options between August 8, 2023 and November 28, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/EGRX.

NEW YORK, NY / ACCESSWIRE / February 9, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/eagle-pharmaceuticals-inc-lawsuit-submission-form?prid=66572&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESSWIRE / February 9, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/eagle-pharmaceuticals-inc-lawsuit-submission-form?prid=66547&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK , Feb. 9, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Eagle Pharmaceuticals, Inc.. Shareholders who purchased shares of EGRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

NEW YORK, NY / ACCESSWIRE / February 9, 2024 / If you suffered a loss on your Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/eagle-pharmaceuticals-inc-lawsuit-submission-form?prid=66546&wire=1 or contact Joseph E. Levi, Esq.